{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:38:55Z","timestamp":1694630335780},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2002,1]]},"DOI":"10.1007\/s11908-002-0067-2","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T12:57:41Z","timestamp":1180097861000},"page":"50-58","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recent advances and new challenges in travel medicine"],"prefix":"10.1007","volume":"4","author":[{"given":"Lin H.","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary E.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"67_CR1","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1086\/319234","volume":"32","author":"JS Keystone","year":"2001","unstructured":"Keystone JS, Kozarsky PE, Freedman DO: Internet and computer-based resources for travel medicine practitioners. Clin Infect Dis 2001, 32:757\u2013765. This is a very thorough compilation of Internet and computer software for travel medicine practitioners.","journal-title":"Clin Infect Dis"},{"key":"67_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1386-5056(97)00079-8","volume":"47","author":"J Woodall","year":"1997","unstructured":"Woodall J: Official versus unofficial outbreak reporting through the internet. Int J Med Infect 1997, 47:31\u201334.","journal-title":"Int J Med Infect"},{"key":"67_CR3","first-page":"21","volume":"50","author":"CDC","year":"2001","unstructured":"CDC: Update: outbreak of acute febrile illness among athletes participating in Eco-Challenge-Sabah 2000: Borneo, Malaysia, 2000. MMWR 2001, 50:21\u201324.","journal-title":"MMWR"},{"key":"67_CR4","first-page":"359","volume":"50","author":"CDC","year":"2001","unstructured":"CDC: Public health dispatch: update: outbreak of acute febrile respiratory illness among college students: Acapulco, Mexico, March 2001. MMWR 2001, 50:359\u2013360.","journal-title":"MMWR"},{"key":"67_CR5","unstructured":"WHO: WHO Fact Sheet No. 94: malaria. Accessible at http:\/\/www.who.int\/inf-fs\/en\/fact094.html."},{"key":"67_CR6","first-page":"25","volume":"50","author":"CDC","year":"2001","unstructured":"CDC: Malaria surveillance - United States, 1997. MMWR 2001, 50(ss-1):25\u201344.","journal-title":"MMWR"},{"key":"67_CR7","first-page":"1","volume":"50","author":"CDC","year":"2001","unstructured":"CDC: Malaria surveillance - United States, 1996. MMWR 2001, 50(ss-1):1\u201322.","journal-title":"MMWR"},{"key":"67_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0035-9203(00)90447-4","volume":"94","author":"A Sabchareon","year":"2000","unstructured":"Sabchareon A, Attanath P, Phanuaksook P, et al.: Efficacy and pharmacokinetic of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2000, 94:77\u201382.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"67_CR9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.1999.60.533","volume":"60","author":"S Looareesuwan","year":"1999","unstructured":"Looareesuwan S, Chulay JD, Canfield CJ, et al.: Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Am J Trop Med Hyg 1999, 60:533\u2013541.","journal-title":"Am J Trop Med Hyg"},{"key":"67_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0149-2918(99)80006-X","volume":"21","author":"M Mulenga","year":"1999","unstructured":"Mulenga M, Sukwa TY, Canfield CJ, et al.: Atovaquone and proguanil versus pyrimethamine\/sulfadoxine for the treatment of acute falciparum malaria in Zambia. Clin Ther 1999, 21:841\u2013852.","journal-title":"Clin Ther"},{"key":"67_CR11","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4269\/ajtmh.1999.60.526","volume":"60","author":"S Looareesuwan","year":"1999","unstructured":"Looareesuwan S, Wilairatana P, Chalermarut K, et al.: Efficacy and safety of atovaquone\/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 1999, 60:526\u2013532.","journal-title":"Am J Trop Med Hyg"},{"key":"67_CR12","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/S0140-6736(96)90671-6","volume":"347","author":"PD Radloff","year":"1996","unstructured":"Radloff PD, Philipps J, Nkeyi M, et al.: Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996, 347:1511\u20131514.","journal-title":"Lancet"},{"key":"67_CR13","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1086\/516497","volume":"175","author":"FEC de Alencar","year":"1997","unstructured":"de Alencar FEC, Cerutti C Jr, Durlacher RR, et al.: Atovaquone and proguanil for the treatment of malaria in Brazil. J Infect Dis 1997, 175:1544\u20131547.","journal-title":"J Infect Dis"},{"key":"67_CR14","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1086\/314770","volume":"179","author":"DG Bustos","year":"1999","unstructured":"Bustos DG, Canfield CJ, Canete-Miguel E, et al.: Atovaquoneproguanil compared with chloroquine and chloroquinesulfadoxine-pyrimethamine for treatment of acute Plasmodium falciparum malaria in the Philippines. J Infect Dis 1999, 179:1587\u20131590.","journal-title":"J Infect Dis"},{"key":"67_CR15","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/00006454-199905000-00011","volume":"18","author":"G Anabwani","year":"1999","unstructured":"Anabwani G, Canfield CJ, Hutchinson DB, et al.: Combination atovaquone and proguanil hydrochloride vs. halofantrine for treatment of acute Plasmodium falciparum malaria in children. Pediatr Infect Dis J 1999, 18:456\u2013461.","journal-title":"Pediatr Infect Dis J"},{"key":"67_CR16","first-page":"106","volume-title":"Health Information for International Travel 2001\u20132002","author":"CDC","year":"2001","unstructured":"CDC: Specific recommendations for vaccinations and disease prevention: malaria. In Health Information for International Travel 2001\u20132002. Atlanta: US Department of Health and Human Services, Public Health Service; 2001:106\u2013120."},{"key":"67_CR17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1086\/514710","volume":"27","author":"GD Shanks","year":"1998","unstructured":"Shanks GD, Gordon DM, Klotz FW, et al.: Efficacy and safety of atovaquone\/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998, 27:494\u2013499.","journal-title":"Clin Infect Dis"},{"key":"67_CR18","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4269\/ajtmh.1999.60.521","volume":"60","author":"TY Sukwa","year":"1999","unstructured":"Sukwa TY, Mulenga M, Chisdaka N, et al.: A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone\/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999, 60:521\u2013525.","journal-title":"Am J Trop Med Hyg"},{"key":"67_CR19","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/S0140-6736(00)03260-8","volume":"356","author":"B Hogh","year":"2000","unstructured":"Hogh B, Clarke PD, Camus D, et al.: Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in non-immune travelers: a randomized, double-blind study. Lancet 2000, 356:1888\u20131894.","journal-title":"Lancet"},{"key":"67_CR20","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1086\/322694","volume":"33","author":"D Overbosch","year":"2001","unstructured":"Overbosch D, Schilthuis H, Bienzle U, et al.: Atovaquoneproguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, doubleblind study. Clin Infect Dis 2001, 33:1015\u20131021.","journal-title":"Clin Infect Dis"},{"key":"67_CR21","unstructured":"US Department of Commerce: 2000 profile of US resident travelers visiting overseas destinations. Reported from: survey of international air travelers. Accessible at http:\/\/www.tinet.ita.doc.gov."},{"key":"67_CR22","first-page":"286","volume":"12","author":"CD Ericcson","year":"1998","unstructured":"Ericcson CD: Travelers\u2019 diarrhea: epidemiology, prevention, and self-treatment. Infect Dis Clin North Am 1998, 12:286\u2013303. This is a comprehensive review of travelers\u2019 diarrhea regarding etiology, prevention, and empiric therapy.","journal-title":"Infect Dis Clin North Am"},{"key":"67_CR23","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1086\/318119","volume":"31","author":"JA Adachi","year":"2000","unstructured":"Adachi JA: Empirical antimicrobial therapy for traveler\u2019s diarrhea. Clin Infect Dis 2000, 31:1079\u20131083.","journal-title":"Clin Infect Dis"},{"key":"67_CR24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1086\/516303","volume":"26","author":"CW Hoge","year":"1998","unstructured":"Hoge CW, Gambel JM, Srijan A, et al.: Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998, 26:341\u2013345.","journal-title":"Clin Infect Dis"},{"key":"67_CR25","doi-asserted-by":"crossref","unstructured":"Hakanen A, Kotilainen P, Huovinen P, et al.: Reduced fluoroquinolone susceptibility in Salmonella enterica serotypes in travelers returning from Southeast Asia. Emerg Infect Dis 2001, 7:In press.","DOI":"10.3201\/eid0706.010613"},{"key":"67_CR26","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/clinids\/21.3.536","volume":"21","author":"RA Kuschner","year":"1995","unstructured":"Kuschner RA, Trofa AF, Thomas RJ, et al.: Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995, 21:536\u2013541.","journal-title":"Clin Infect Dis"},{"key":"67_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/jmv.1890440428","volume":"44","author":"R Steffen","year":"1994","unstructured":"Steffen R, Gyurech D: Advances in hepatitis A prevention in travelers. J Med Virol 1994, 44:460\u2013462.","journal-title":"J Med Virol"},{"key":"67_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/j.1708-8305.1998.tb00468.x","volume":"5","author":"S Iwarson","year":"1998","unstructured":"Iwarson S: What type of travelers would benefit from combined vaccination against hepatitis A and B?\n                           J Travel Med 1998, 5:80\u201383.","journal-title":"J Travel Med"},{"key":"67_CR29","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/0264-410X(93)90221-I","volume":"11","author":"R Steffen","year":"1993","unstructured":"Steffen R: Hepatitis A and B: risks compared with other vaccine-preventable diseases and immunization recommendations. Vaccine 1993, 11:518\u2013520.","journal-title":"Vaccine"},{"key":"67_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2310\/7060.2001.24033","volume":"8","author":"JD Correia","year":"2001","unstructured":"Correia JD, Shafer RT, Patel V, et al.: Blood and body fluid exposure as a health risk for international travelers. J Travel Med 2001, 8:263\u2013266.","journal-title":"J Travel Med"},{"key":"67_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2310\/7060.2000.00054","volume":"7","author":"JN Zuckerman","year":"2000","unstructured":"Zuckerman JN, Steffen R: Risks of hepatitis B in travelers as compared to immunization status. J Travel Med 2000, 7:170\u2013174.","journal-title":"J Travel Med"},{"key":"67_CR32","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0264-410X(98)00421-6","volume":"17","author":"S Thoelen","year":"1999","unstructured":"Thoelen S, Van Damme P, Leentvaar-Kuypers A, et al.: The first combined vaccine against hepatitis A and B: an overview. Vaccine 1999, 17:1657\u20131662.","journal-title":"Vaccine"},{"key":"67_CR33","first-page":"806","volume":"50","author":"CDC","year":"2001","unstructured":"CDC. Notice to readers: FDA approval for a combined hepatitis A and B vaccine. MMWR 2001, 50:806\u2013807.","journal-title":"MMWR"},{"key":"67_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0264-410X(00)00166-3","volume":"19","author":"B Kallinowski","year":"2001","unstructured":"Kallinowski B, Knoll A, Lindner E, et al.: Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A\/B vaccine during the primary immunization course?\n                           Vaccine 2001, 19:16\u201322.","journal-title":"Vaccine"},{"key":"67_CR35","first-page":"897","volume":"50","author":"CDC","year":"2001","unstructured":"CDC: Weekly update: West Nile virus activity - United States, October 10\u201316, 2001. MMWR 2001, 50:897\u2013898.","journal-title":"MMWR"},{"key":"67_CR36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.4269\/ajtmh.2000.62.631","volume":"62","author":"CA Johansen","year":"2000","unstructured":"Johansen CA, van Hurk AF, Ritchie SA, et al.: Isolation of Japanese encephalitis virus from mosquitoes (Diptera: Culicidae) collected in the Western Province of Papua New Guinea, 1997\u20131998. Am J Trop Med Hyg 2000, 62:631\u2013638.","journal-title":"Am J Trop Med Hyg"},{"key":"67_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0891-5520(05)70221-X","volume":"14","author":"RE Isturiz","year":"2000","unstructured":"Isturiz RE, Gubler DJ, del Castillo JB: Dengue and dengue hemorrhagic fever in Latin America and the Caribbean. Infect Dis Clin North Am 2000, 14:121\u2013140. Good general review of dengue, with special attention to history and spread in the Americas.","journal-title":"Infect Dis Clin North Am"},{"key":"67_CR38","first-page":"248","volume":"49","author":"CDC","year":"2000","unstructured":"CDC: Imported dengue - United States, 1997 and 1998. MMWR 2000, 49:248\u2013253.","journal-title":"MMWR"},{"key":"67_CR39","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1086\/313889","volume":"31","author":"T Jelinek","year":"2000","unstructured":"Jelinek T: Dengue fever in international travelers. Clin Infect Dis 2000, 31:144\u2013147.","journal-title":"Clin Infect Dis"},{"key":"67_CR40","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3201\/eid0506.990615","volume":"5","author":"I Postasman","year":"1999","unstructured":"Postasman I, Srugo I, Schwartz E: Dengue seroconversion among Israeli travelers to tropical countries. Emerg Infect Dis 1999, 5:824\u2013827.","journal-title":"Emerg Infect Dis"},{"key":"67_CR41","first-page":"643","volume":"50","author":"CDC","year":"2001","unstructured":"CDC: Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996\u20132001. MMWR 2001, 50:643\u2013645.","journal-title":"MMWR"},{"key":"67_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(01)05341-7","volume":"358","author":"RC Chan","year":"2001","unstructured":"Chan RC, Penney DJ, Little D, et al.: Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001, 358:121\u2013122.","journal-title":"Lancet"},{"key":"67_CR43","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S0140-6736(01)05374-0","volume":"358","author":"P Marianneau","year":"2001","unstructured":"Marianneau P, George-Courbot M-C, Deubel V: Rarity of adverse effects after 17D yellow-fever vaccination. Lancet 2001, 358:84\u201385.","journal-title":"Lancet"},{"key":"67_CR44","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","volume":"358","author":"M Martin","year":"2001","unstructured":"Martin M, Tsai TF, Cropp B, et al.: Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001, 358:98\u2013104.","journal-title":"Lancet"},{"key":"67_CR45","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","volume":"358","author":"PFC Vasconcelos","year":"2001","unstructured":"Vasconcelos PFC, Lund EJ, Galler R, et al.: Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358:91\u201397.","journal-title":"Lancet"},{"key":"67_CR46","doi-asserted-by":"crossref","unstructured":"Martin M, Weld LH, Tsai TF et al.: Advanced age a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001, 7:In press.","DOI":"10.3201\/eid0706.010605"},{"key":"67_CR47","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/S0091-6749(99)70245-9","volume":"4","author":"JM Kelso","year":"1999","unstructured":"Kelso JM, Mootrey GT, Tsai TF: Anaphylaxis from yellow ever vaccine. J Allergy Clin Immunol 1999, 4:698\u2013701.","journal-title":"J Allergy Clin Immunol"},{"key":"67_CR48","first-page":"345","volume":"49","author":"CDC","year":"2000","unstructured":"CDC: Serogroup W-135 meningococcal disease among travelers returning from Saudi Arabia - United States, 2000. MMWR 2000, 49:345\u2013346.","journal-title":"MMWR"},{"key":"67_CR49","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/S0140-6736(00)03502-9","volume":"356","author":"M-K Taha","year":"2000","unstructured":"Taha M-K, Achtman M, Alonso J-M, et al.: Serogroup W135 meningococcal disease in Hajj pilgrims. Lancet 2000, 356:2159.","journal-title":"Lancet"},{"key":"67_CR50","first-page":"221","volume":"50","author":"CDC","year":"2001","unstructured":"CDC: Update: assessment of risk for meningococcal disease associated with the Hajj 2001. MMWR 2001, 50:221\u2013222.","journal-title":"MMWR"},{"key":"67_CR51","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3201\/eid0604.000423","volume":"6","author":"T Popovic","year":"2000","unstructured":"Popovic T, Sacchi CT, Reeves MW, et al.: Neisseria meningitidis serogroup W125 isolates associated with the ET-37 complex. Emerg Infect Dis 2000, 6:428\u2013429.","journal-title":"Emerg Infect Dis"},{"key":"67_CR52","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1086\/313974","volume":"31","author":"JE Miller","year":"2000","unstructured":"Miller JE, Tam TWS, Maloney S, et al.: Cruise ships: high-risk passengers and the global spread of new influenza viruses. Clin Infect Dis 2000, 31:433\u2013438.","journal-title":"Clin Infect Dis"},{"key":"67_CR53","first-page":"685","volume":"47","author":"CDC","year":"1998","unstructured":"CDC: Update: outbreak of influenza A infection: Alaska and the Yukon Territory, July-August 1998. MMWR 1998, 47:685\u2013688.","journal-title":"MMWR"},{"key":"67_CR54","first-page":"137","volume":"50","author":"CDC","year":"2001","unstructured":"CDC: Influenza B virus outbreak on a cruise ship - northern Europe, 2000. MMWR 2001, 50:137\u2013140.","journal-title":"MMWR"},{"key":"67_CR55","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1086\/322013","volume":"184","author":"JA Buxton","year":"2001","unstructured":"Buxton JA, Skowronski DM, Ng H: Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks. J Infect Dis 2001, 184:188\u2013191.","journal-title":"J Infect Dis"},{"key":"67_CR56","first-page":"855","volume":"50","author":"CDC","year":"2001","unstructured":"CDC: Update: outbreak of poliomyelitis - Dominican Republic and Haiti. MMWR 2001, 50:855\u2013856.","journal-title":"MMWR"},{"key":"67_CR57","first-page":"874","volume":"50","author":"CDC","year":"2001","unstructured":"CDC: Public health dispatch: acute flaccid paralysis associated with circulating vaccine-derived poliovirus - Philippines, 2001. MMWR 2001, 50:874\u2013875.","journal-title":"MMWR"},{"key":"67_CR58","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1001\/jama.283.20.2668","volume":"283","author":"M-L Akers","year":"2000","unstructured":"Akers M-L, Puhr ND, Tauxe RV, et al.: Laboratory-based surveillance of Salmonella serotype typhi infections in the United States. JAMA 2000, 283:2668\u20132673.","journal-title":"JAMA"},{"key":"67_CR59","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0140-6736(99)01001-6","volume":"353","author":"J Threlfall","year":"1999","unstructured":"Threlfall J, Ward LR, Skinner JA, et al.: Ciprofloxacin-resistant Salmonella typhi and treatment failure. Lancet 1999, 353:1590\u20131591.","journal-title":"Lancet"},{"key":"67_CR60","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0035-9203(98)90891-4","volume":"92","author":"NTT Hoa","year":"1998","unstructured":"Hoa NTT, Diep TS, Wain J, et al.: Community-acquired septicaemia in southern Viet Nam: the importance of multidrug-resistant Salmonella typhi. Trans R Soc Trop Med Hyg 1998, 92:503\u2013508.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"67_CR61","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(00)02554-X","volume":"356","author":"FGJ Cobelens","year":"2000","unstructured":"Cobelens FGJ, van Deutekom H, Draayer-Jansen IWE, et al.: Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 2000, 356:461\u2013465. This is an excellent study illustrating the risk of tuberculosis in travelers.","journal-title":"Lancet"},{"key":"67_CR62","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/00063198-200105000-00006","volume":"7","author":"PA Willcox","year":"2001","unstructured":"Willcox PA: Drug-resistant tuberculosis: worldwide trends, problems specific to Eastern Europe and other hotspots, and the threat to developing countries. Curr Opin Pulm Med 2001, 7:148\u2013153.","journal-title":"Curr Opin Pulm Med"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-002-0067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11908-002-0067-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-002-0067-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-002-0067-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T09:56:40Z","timestamp":1659088600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11908-002-0067-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["67"],"URL":"https:\/\/doi.org\/10.1007\/s11908-002-0067-2","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}